Leo Pharma expands its arsenal of arguments for Adtralza with new long-term data

While Leo Pharma is in full swing with getting eczema treatment Adtralza onto the market, and is anxiously waiting on US approval, the company has presented new long-term data for the drug, causing excitement.

Photo: Leo Pharma / PR

Leo Pharma has been developing the medicine tralokinumab for so long that it can now present data for the treament stretching over two years. The drug was already approved earlier this year as a treatment for atopic dermatitis in the EU under the name Adtralza.

The company's new data was presented at the conference for the European Academy of Dermatology and Venereology (EADV), and according to Vice President at Leo Pharma Bo Bang, Leo Pharma now has an ace up its sleeve.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs